The FDA Grants Fast Track Designation To Zymeworks' ZW191 For Advanced Or Metastatic Platinum-Resistant Ovarian Cancer

Zymeworks has received Fast Track designation from the FDA for its antibody-drug conjugate ZW191, aimed at treating advanced or metastatic platinum-resistant ovarian cancer. ZW191 targets the FRα protein, present in about 75% of high-grade serous ovarian carcinomas, and is currently being evaluated in a Phase 1 clinical study to assess its safety and preliminary anti-tumor activity. This designation is intended to expedite the drug's development and review process, highlighting its potential to address significant unmet medical needs.